Lexicon Pharmaceuticals, Inc. (LXRX): Cash & Equivalents
$34.33M
As of 2025-12-31
$40.92M
As of 2026-06-30
-9.5%
3-year compound annual growth
-22.9%
5-year compound annual growth
-16.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.33M | -48.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $66.66M | +196.7% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $22.46M | -51.5% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $46.34M | -27.7% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $64.06M | -49.3% | 2023-03-03, Balance as of period end |
| 2020-12-31 | $126.26M | +249.6% | 2023-03-03, Balance as of period end |
| 2019-12-31 | $36.11M | -55.1% | 2022-03-10, Balance as of period end |
| 2018-12-31 | $80.39M | +30.4% | 2021-03-12, Balance as of period end |
| 2017-12-31 | $61.66M | +32.3% | 2020-03-12, Balance as of period end |
| 2016-12-31 | $46.60M | -77.0% | 2019-03-15, Balance as of period end |
| 2015-12-31 | $202.99M | +47.9% | 2018-03-01, Balance as of period end |
| 2014-12-31 | $137.27M | +266.1% | 2017-03-06, Balance as of period end |
| 2013-12-31 | $37.50M | +23.3% | 2016-03-11, Balance as of period end |
| 2012-12-31 | $30.42M | -83.7% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $186.31M | +294.7% | 2014-03-07, Balance as of period end |
| 2010-12-31 | $47.21M | -53.1% | 2013-03-11, Balance as of period end |
| 2009-12-31 | $100.55M | n/a | 2012-03-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $89.13M | +16.9% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
Compare LXRX, GOSS, OCUL, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗